Categories
News World

Global Anti-obesity Drugs Market Research Report 2020

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Anti-obesity Drugs market.

Trusted Business Insights presents an updated and Latest Study on Anti-obesity Drugs Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Anti-obesity Drugs market during the forecast period (2020-2029).
It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Anti-obesity Drugs Market Research Report 2020

Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain dieting and physical exercise.
The report analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 41.45 percent over the period 2013-2022.

The global Anti-obesity Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.

This report focuses on Anti-obesity Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-obesity Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

  • Merck
  • Novo Nordisk
  • Pfizer
  • Arena Pharmaceuticals
  • Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus
  • Amylin
  • Alizyme
  • Boehringer Ingelheim
  • Eisai

Segment by Regions

  • North America
  • Europe
  • China
  • Japan

Segment by Type

  • Peripherally Acting Anti-obesity Drugs
  • Centrally Acting Anti-obesity Drugs

Segment by Application

  • Kids
  • Adults

In Aug 2020, Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A),Hanmis investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH).

Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercializeefinopegdutidein the United States and globally. Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide,as well as double-digit royalties on sales of approved product. Hanmi retains an option to commercialize efinopegdutide in Korea.

Efinopegdutide is a GLP-1/glucagon receptor dual agonist, which activates both the GLP-1 and glucagon receptors. The safety and efficacy of efinopegdutide has previously been evaluated in multiple Phase 1 and Phase 2 clinical trials, including for the treatment of severely obese individuals with and without type 2 diabetes mellitus.

Research Methodology: Global Metabolic Disorder Therapeutics Market

  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.

 

Looking for more? Check out our repository for all available reports on Anti-obesity Drugs in related sectors.

Quick Read Table of Contents of this Report @ Global Anti-obesity Drugs Market Research Report 2020

Contacts

Trusted Business Insights
Shelly Arnold
Media & Marketing Executive
Email Me For Any Clarifications
Connect on LinkedIn
Click to follow Trusted Business Insights LinkedIn for Market Data and Updates.
US: +1 646 568 9797
UK: +44 330 808 0580

Categories
News

Anti-Obesity Drugs Booming Segments; Investors Seeking Growth

A New Syndicate COVID-19 Outbreak-Global Anti-Obesity Drugs Market Study is added in HTF MI database compiled covering key business segments and wider geographical scope to get deep dive analysed market data. The study brings a perfect bridging between qualitative and statistical data of COVID-19 Outbreak- Anti-Obesity Drugs market. The study provides historical data (i.e. Consumption** & Value) from 2014 to 2019 and forecasted till 2026*. Some are the key & emerging players that are part of coverage and have being profiled are Vivus, Rhythm Pharmaceuticals, F. Hoffmann La Roche, Shionogi USA, GlaxoSmithKline, Orexigen Therapeutics, FlaxoSithKline plc, Zafgen, Takeda Pharmaceutical, Alizyme, Novo Nordisk, Pfizer, Norgine Pharmaceuticals Ltd., Eisai Co, Ltd., BoehringerIngelheim GmbH & Bristol-Myers Squibb.

Know how you are perceived in comparison to your competitors like Vivus, Rhythm Pharmaceuticals, F. Hoffmann La Roche, Shionogi USA, GlaxoSmithKline, Orexigen Therapeutics, FlaxoSithKline plc, Zafgen, Takeda Pharmaceutical, Alizyme, Novo Nordisk, Pfizer, Norgine Pharmaceuticals Ltd., Eisai Co, Ltd., BoehringerIngelheim GmbH & Bristol-Myers Squibb; Get an accurate view of your business in COVID-19 Outbreak-Global Anti-Obesity Drugs Marketplace.

Click to get COVID-19 Outbreak-Global Anti-Obesity Drugs Market Research Sample PDF Copy Instantly

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview

Key Highlights that HTF MI is bringing with this Study
• Revenue splits by most promising business segments. [By Type (, Prescription Drugs & OTC Drugs), By Application (Men & Women) and any other business Segment if applicable within scope of report]
• Gap Analysis by Region. Country Level Break-up to dig out Trends and emerging opportunity available in area of your business interest.
• % Market Share & Sales Revenue by Key Players & Local Regional Players .
• Dedicated Section on Market Entropy to gain insights on Players aggressive Strategies to built market [Merger & Acquisition / Recent Funding & Investment and Key Developments]
• Patent Analysis** No of patents / Trademark approval filed & received in recent years.
• Competitive Landscape: Listed Players Company profile with SWOT, In-depth Overview, Product/Services Specification, Headquarter, Subsidiaries, Downstream Buyers and Upstream Suppliers.

Check Exclusive Discount Offers Available On this Report @ https://www.htfmarketreport.com/request-discount/2836664-covid-19-outbreak-global-anti-obesity-drugs-industry-market-1

Competitive Landscape:

Mergers & Acquisitions, Agreements & Collaborations, New Product Launches, Business overview & detailed matrix of Product for each player listed in the study. Players exclusively profiled are Vivus, Rhythm Pharmaceuticals, F. Hoffmann La Roche, Shionogi USA, GlaxoSmithKline, Orexigen Therapeutics, FlaxoSithKline plc, Zafgen, Takeda Pharmaceutical, Alizyme, Novo Nordisk, Pfizer, Norgine Pharmaceuticals Ltd., Eisai Co, Ltd., BoehringerIngelheim GmbH & Bristol-Myers Squibb

Most frequently asked question:
Why i can’t See My company Profiled in the Study?
Yes, It might be a possibility that Company you are looking for is not listed, however study is based on vast coverage of players operating in but due to limited scope and pricing constraints we can only list few random companies keeping a mix of leaders and emerging players. Do contact us if you wish to see any specific company of your interest in the survey. Currently list of companies available in the study are Vivus, Rhythm Pharmaceuticals, F. Hoffmann La Roche, Shionogi USA, GlaxoSmithKline, Orexigen Therapeutics, FlaxoSithKline plc, Zafgen, Takeda Pharmaceutical, Alizyme, Novo Nordisk, Pfizer, Norgine Pharmaceuticals Ltd., Eisai Co, Ltd., BoehringerIngelheim GmbH & Bristol-Myers Squibb

Segment & Regional Analysis: What Market breakdown Would be Covered by geographies, Type & Application/End-users
• COVID-19 Outbreak- Anti-Obesity Drugs Market Revenue & Growth Rate by Type [, Prescription Drugs & OTC Drugs] (Historical & Forecast)
• COVID-19 Outbreak-Global Anti-Obesity Drugs Market Revenue & Growth Rate by Application [Men & Women] (Historical & Forecast)
• COVID-19 Outbreak- Anti-Obesity Drugs Market Revenue & Growth Rate by Each Region Specified (Historical & Forecast)
• COVID-19 Outbreak- Anti-Obesity Drugs Market Volume & Growth Rate by Each Region Specified, Application & Type (Historical & Forecast)
• COVID-19 Outbreak- Anti-Obesity Drugs Market Revenue, Volume & Y-O-Y Growth Rate by Players (Base Year)

Enquire for customization in Report @ https://www.htfmarketreport.com/enquiry-before-buy/2836664-covid-19-outbreak-global-anti-obesity-drugs-industry-market-1

To comprehend COVID-19 Outbreak-Global Anti-Obesity Drugs market dynamics in the world mainly, the worldwide COVID-19 Outbreak- Anti-Obesity Drugs market is analyzed across major global regions. HTF also provides customized regional and country-level reports

• North America: United States, Canada, and Mexico.
• South & Central America: Argentina, Chile, Colombia and Brazil.
• Middle East & Africa: Saudi Arabia, United Arab Emirates, Israel, Turkey, Egypt, Tunisia and South Africa.
• Europe: United Kingdom, France, Poland, Italy, Germany, Spain, NORDIC {Sweden, Norway, Finland, Denmark etc}, BENELUX {Belgium, The Netherlands, Luxembourg },and Russia.
• Asia-Pacific: SAARC Nations, China, Japan, South Korea, Southeast Asia, New Zealand & Australia.

Actual Numbers & In-Depth Analysis with emerging trends of COVID-19 Outbreak- Anti-Obesity Drugs Market Size Estimation Available in Full Copy of Report.

Buy Full Copy of COVID-19 Outbreak-Global Anti-Obesity Drugs Market Latest Released Edition

Thanks for reading this article, you can also get individual chapter or section or regional study by limiting the scope to just G7 or G20 or European Union Countries, Eastern Europe, East Asia or Southeast Asia.

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
[email protected]

Connect with us at LinkedIn | Facebook | Twitter